Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Connect MM- The Multiple Myeloma Disease Registry

Trial Profile

Connect MM- The Multiple Myeloma Disease Registry

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 01 Dec 2018 Results assessing the patient reported outcomes from Cohort 1 in patients with NDMM who received ASCT and did or did not receive maintenance therapy, published in the Annals of Hematology
    • 12 Jul 2018 Results published in the Clinical Therapeutics
    • 05 Jun 2018 Results assessing predictors of long-term survival by using data from this study presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top